Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Post by saveyourselfnowon Aug 17, 2018 7:31am
131 Views
Post# 28476373

PROF creates propaganda - here is a real news story...

PROF creates propaganda - here is a real news story...see if you can spot the difference between PROF's fantasies and real news.

Globe says Canopy Growth hiked to "speculative buy"

Canopy Growth Corp (C:WEED)
Shares Issued 220,585,018
Last Close 8/16/2018 $40.68
Friday August 17 2018 - In the News

The Globe and Mail reports in its Friday edition that Canaccord analyst Matt Bottomley is upbeat on Constellation Brands' $5-billion bet on Canopy Growth ($40.68). The Globe's David Leeder writes that Mr. Bottomley boosted his rating on Canopy to "speculative buy" from "hold." Mr. Bottomley hiked his share target to $50 from $34. Analysts on average target the shares at $45.17. Mr. Bottomley says in a note: "We believe this represents a transformational event for Canopy (and the industry as a whole) in the form of a substantial commitment from an established, international partner that is a top tier producer/distributor of alcohol worldwide. More importantly, even prior to this deal, we believe Canopy had a top-three presence on the global cannabis stage in the 11 countries where it has secured exposure. With $5-billion slated to hit the balance sheet later in October, we believe Canopy is now second to none with its ability to expand this platform even further; with 12 times more cash than its largest Canadian competitors at this time. As a result, we believe the company is substantially better suited to execute on a global first mover advantage with the capital and strategic leverage provided by Constellation."

© 2018 Canjex Publishing Ltd.

Bullboard Posts